A617/0263

Herceptin drug and breast cancer cell. Molecular model of Herceptin (Trastuzumab), showing the molecule's secondary structure, seen as alpha helices (coils) and beta sheets (arrows). A breast cancer cell is at lower left (blue). Herceptin binds to HER2 (human epidermal growth factor receptor 2), a receptor that is over-expressed in some breast cancer cells, making them grow faster and more likely to spread. Herceptin blocks HER2, which kills the breast cancer cells. Around a fifth of breast cancers result from cells that over-express HER2, making them viable for Herceptin treatment.

TRASTUZUMAB

HERCEPTIN

DRUG

MOLECULE

PROTEIN

MONOCLONAL ANTIBODY

CELL

BIOCHEMISTRY

BIOLOGY

CHEMISTRY

MEDICINE

PHARMACOLOGY

IMMUNOLOGY

ONCOLOGY

ARTWORK

ILLUSTRATION

MOLECULAR MODEL

ABNORMAL

ALPHA HELIX

BALLS

BETA SHEET

BIOCHEMICAL

BIOLOGICAL

BREAST CANCER

CANCER DRUG

CANCER TREATMENT

CANCEROUS

CHEMICAL

CHEMOTHERAPY

COMPOUND

COMPOUNDS

CUT OUT

CUT-OUT

CUTOUT

DOTS

HELICES

HELIXES

HER2

HUMAN EPIDERMAL GROWTH FACTOR

MALIGNANCY

MALIGNANT

MEDICAL

MOLECULAR

MOLECULES

PHARMACOLOGICAL

PROTEINS

RECEPTOR 2

SCANNING ELECTRON MICROGRAPH

SECONDARY STRUCTURE

SEM

SHEETS

THERAPY

TREATMENT

TUMOUR

UNHEALTHY

Done